HRMY at a glance
Harmony Biosciences Holdings, Inc. (HRMY, SEC CIK 1802665) filed its latest 10-K annual report on February 24, 2026, a 10-Q quarterly report on November 4, 2026, an 8-K current report on November 4, 2026 and Form 4 insider filings as recently as September 18, 2026. SignalX summarizes each filing with AI and tracks the company's insider trades and institutional holders.
- For the fiscal year ended December 31, 2025 (FY2025), Harmony Biosciences Holdings, Inc. (HRMY) reported revenue of $868.5 million (up 21.5% from FY2024) and net income of $158.7 million. Diluted EPS was $2.71.
- As of September 30, 2026, 32 institutional investment managers tracked by SignalX reported holding Harmony Biosciences Holdings, Inc. (HRMY) shares worth $1.0 billion in 13F-HR filings.
- The most recent insider open-market sale reported on Form 4 was by Budur Kumar on September 18, 2026 of 35,852 shares at $43.05 per share.
- In the last 90 days, HRMY insiders reported 0 open-market purchases ($0) and 7 open-market sales ($3.1M) on Form 4, a net sale of $3.1M.
Source: SEC EDGAR (XBRL financial data, 13F-HR and Form 4 filings).
- Revenue · FY2025
- $868.5M
- +21.5% vs prior year
- Insiders · 90 days
- 0 buys · 7 sells
- Net −$3.1M
- 13F holders
- 32 funds
- $1.0B · +0 vs prior quarter
- Latest 8-K
- Nov 4, 2026
- Item 2.02 · Item 7.01
AI 10-K Annual Report Analysis
Latest 10-K, fiscal year ended Dec 31, 2025
Business Overview
- Core business: Neuroscience-focused biopharma developing innovative treatments for rare neurological diseases emphasizing sleep/wake disorders, rare epilepsy, and neurobehavioral conditions
- New products and expansions: Acquired orexin 2 receptor agonist BP1.15205 (preclinical), launched Phase 3 trials for next-gen pitolisant formulations (GR and HD), expanded rare epilepsy pipeline via Epygenix acquisition with EPX-100 and EPX-200
- Strategic shift: Diversified beyond pitolisant with Zynerba acquisition (ZYN002 cannabidiol gel), entry into orexin science, and cell replacement therapy collaboration with CiRC Biosciences
- Quantitative highlight: WAKIX net revenue $868.5M in 2025 with ~8,500 average patients on therapy; filed NDA for Pitolisant GR targeting Q1 2027 FDA review
- Noteworthy: FDA approvals expanded WAKIX pediatric indications for EDS (2024) and cataplexy (2026); Phase 3 negative RECONNECT trial led to phasing out ZYN002 in Fragile X syndrome
Risk Factors
- Regulatory risk: FDA post-marketing requirements and commitments for WAKIX, including recent approvals for pediatric narcolepsy in June 2024 and February 2026
- Geopolitical/macroeconomic risk: reliance on third-party manufacturing with sole-source suppliers and manufacturers, exposing supply chain to disruption risks
- Operational risk: dependence on Bioprojet license for core pitolisant IP, with risk of termination restricting commercialization rights in the U.S.
- Competitive risk: WAKIX faces competition from modafinil, which showed non-inferiority, potentially limiting physician prescribing and market acceptance
- Financial risk: dependence on WAKIX sales for substantially all revenue, with failure to grow sales potentially causing loss of profitability and need for additional financing
Management Discussion & Analysis
- Revenue $868.5M, up 21.5% YoY (+$153.7M) driven by 18.3% volume growth and 7.0% price increase, offset by 3.6% higher rebates
- Gross margin 77.2% (cost of sales 22.8%) vs 78.1% (cost of sales 21.9%) in prior year, impacted by higher royalty tier
- R&D expenses $189.6M, up 30.0% (+$43.8M) led by EPX-100 (+$27.2M), ZYN002 (+$8.0M), and Pitolisant GR/HD (+$11.9M); offset by $7.7M decrease for Pitolisant IH
- Net income $158.7M, up from $145.5M; Operating income $208.5M vs $190.8M prior year
- Capital allocation: no specific buybacks or dividends disclosed; $0.5M rent/consulting fees; increased investments in clinical trials and manufacturing; forward-looking focus on advancing multiple Phase 3 programs and pursuing pediatric exclusivity with potential PDUFA dates in 2027-2028
AI summary of the HRMY 10-K filed . Generated from the filing text; verify against the original.View on SEC EDGARHow to read a 10-K
AI 10-Q Quarterly Report Analysis
Latest 10-Q, quarter ended Sep 30, 2026
Management Discussion & Analysis
- Revenue $268.9M, up 12.3% YoY from $239.5M, driven by 7.5% higher units and a 7% price increase
- Gross margin 70.0% vs 75.1% YoY, with cost of product sold rising to 30.0% of revenue from 24.9%
- WAKIX, the sole commercial product, averaged approximately 9,350 patients; formulary access exceeded 80% of insured lives
- Operating cash flow $196.9M year-to-date vs $222.0M, with $307.5M investing outflow including $369.9M debt-security purchases
- Cash, equivalents and investments $1,052.0M; management expects funding for operational needs and potential investments for at least 12 months
Risk Factors
- No material changes to 2025 Form 10-K risk factors as of September 30, 2026
- Previously disclosed risks may materially affect business, financial condition, or operating results
- Unknown or currently immaterial risks could materially adversely affect results
AI summary of the HRMY 10-Q filed . Generated from the filing text; verify against the original.View on SEC EDGAR10-K vs 10-Q vs 8-K
AI 8-K Current Report Analysis
The most recent material events, by 8-K item
Item 2.02: Results of Operations and Financial Condition
- Q3 2026 financial results announced for quarter ended September 30, 2026
- Press release contains the detailed operating results and financial metrics in Exhibit 99.1
Item 7.01: Regulation FD Disclosure
- Investor presentation posted November 4, 2026, providing updated materials for investor and analyst discussions
- Exhibit 99.2 contains the substantive company messaging and should be reviewed for pipeline, financial outlook, and strategic updates
Item EX-99.2: Item EX-99.2
- Q3 2026 WAKIX revenue $268.9M, up 12% year over year, with 400 net patient adds and 9,350 average patients
- 2026 WAKIX revenue guidance reaffirmed at $1.00B-$1.04B, supporting continued commercial momentum
Item EX-99.1: Item EX-99.1
- Q3 WAKIX net revenue $268.9M, up 12% YoY, with 400 net patient adds to 9,350
- Full-year WAKIX guidance reiterated at $1.0B to $1.04B, supporting near-term commercial visibility
Item 5.02: Departure/Appointment of Directors or Principal Officers
- Jeffrey M. Dayno departing, retained as advisor through January 31, 2028
- Dayno consulting compensation: $500 per hour, continued equity vesting, or full vesting upon a change in control
Item 5.02: Departure/Appointment of Directors or Principal Officers
- CEO Jeffrey M. Dayno retiring and leaving the board December 31, 2026, after leadership succession process
- Dayno remaining as non-executive advisor through 2027, supporting transition continuity
Item EX-99.1: Item EX-99.1
- CEO transition effective January 1, 2027: Peter Anastasiou succeeds Jeffrey Dayno, reducing execution uncertainty through internal succession
- Dayno retires December 31, 2026 after nine years and remains a non-executive advisor throughout 2027
Item 7.01: Regulation FD Disclosure
- October 12, 2026 press release announced Harmony Biosciences’ leadership transition
- Leadership change is the core investor-relevant disclosure, with details in Exhibit 99.1
AI summaries of HRMY 8-K current reports filed with the SEC. What 8-K item codes mean
SignalX for HRMY
Don't miss the next HRMY filing
- Alerts as it files. A push when HRMY files an 8-K or an insider trades.
- Fund moves. Which tracked funds opened, added or cut HRMY, by share count.
- Ask anything. An AI agent that reads every HRMY filing and answers with sources.
Recent Insider Transactions (Form 4)
Latest reported trades by officers, directors and 10% owners
| Insider | Type | Date | Shares | Price |
|---|---|---|---|---|
| Budur Kumar | M | Sep 18, 2026 | 25,446 | $30.27 |
| Budur Kumar | M | Sep 18, 2026 | 10,406 | - |
| Budur Kumar | M | Sep 18, 2026 | 10,406 | $30.69 |
| Budur Kumar | M | Sep 18, 2026 | 25,446 | - |
| Budur Kumar | Sell | Sep 18, 2026 | 35,852 | $43.05 |
| Budur Kumar | Sell | Sep 17, 2026 | 800 | $43.00 |
| Budur Kumar | M | Sep 17, 2026 | 400 | $30.69 |
| Budur Kumar | M | Sep 17, 2026 | 400 | - |
Financial SummaryXBRL
| Metric | FY2023 | FY2024 | FY2025 |
|---|---|---|---|
| Profitability | |||
| Revenue | - | $714.7M | $868.5M |
| Gross Profit | - | $557.9M | $670.1M |
| Operating Income | - | $190.8M | $208.5M |
| Net Income | - | $145.5M | $158.7M |
| Gross Margin | - | 78.1% | 77.2% |
| Op. Margin | - | 26.7% | 24.0% |
| Net Margin | - | 20.4% | 18.3% |
| Balance Sheet | |||
| Total Assets | $811.4M | $999.2M | $1.3B |
| Equity | - | $659.2M | $870.2M |
| ROE | - | 22.1% | 18.2% |
| Per Share | |||
| EPS | - | $2.51 | $2.71 |
| Cash Flow | |||
| Operating CF | - | $219.8M | $348.2M |
| CapEx | $312K | $1.2M | $310K |
Source: XBRL data in Harmony Biosciences Holdings, Inc. (HRMY)'s 10-K filings on SEC EDGAR, in USD. Compare across companies →
13F Fund Holdings: Quarterly Trend
Latest: Q3 2026Aggregate HRMY share value held by 13F filers tracked by SignalX, by quarter.
Quarterly totals table
| Quarter | Funds | Total value |
|---|---|---|
| Q3 2026 | 32 | $1.02B |
| Q2 2026 | 32 | $1.01B |
| Q1 2026 | 33 | $805.3M |
| Q4 2025 | 30 | $954.3M |
| Q3 2025 | 31 | $708.9M |
| Q2 2025 | 31 | $801.7M |
| Q1 2025 | 29 | $633.7M |
| Q4 2024 | 25 | $598.1M |
- BlackRock+826.9K (+12%)
- State Street Corp+271.3K (+15%)
- Dimensional Fund Advisors+256.4K (+11%)
- Renaissance Technologies LLC+202.2K (+17%)
- Goldman Sachs Group+184.9K (+46%)
- JPMorgan Chase & Co−450.0K (-88%)
- Millennium Management−298.9K (-93%)
- Citigroup−16.1K (-23%)
- Wells Fargo & Co−10.4K (-23%)
- HANCOCK WHITNEY CORP−496 (-6%)
- Raymond James Financial+100.5K
- Truist Financial+14.5K
- FMR LLC (Fidelity)−3.57M
- Citadel Advisors LLC−255.8K
Source: 13F-HR filings on SEC EDGAR (aggregated from 243 fund-quarter rows). Reflects only 13F filers tracked by SignalX, not the full institutional ownership universe. How 13F filings work
HRMY filing archive
AI analysis pages for each 10-K, 10-Q and 8-K
10-K annual reports
10-Q quarterly reports
Latest 2026 SEC Filings: 10-K, 10-Q, 8-K & Form 4
| Form | Filing date | Period | Analysis | SEC |
|---|---|---|---|---|
| 8-K | Nov 4, 2026 | - | Analysis | - |
| 10-Q | Nov 4, 2026 | Sep 30, 2026 | Analysis | |
| 8-K | Oct 30, 2026 | - | Analysis | - |
| 8-K | Oct 13, 2026 | - | Analysis | - |
| 4 | Sep 18, 2026 | - | - | - |
| 4 | Sep 9, 2026 | - | - | - |
| 10-Q | Aug 4, 2026 | Jun 30, 2026 | Analysis | |
| 8-K | Aug 4, 2026 | - | Analysis | - |
| SC 13G | Jul 31, 2026 | - | - | |
| 8-K | Jul 16, 2026 | - | Analysis | - |
| 4 | May 18, 2026 | - | - | |
| 4 | May 18, 2026 | - | - | |
| 4 | May 18, 2026 | - | - | |
| 4 | May 18, 2026 | - | - | |
| 4 | May 18, 2026 | - | - | |
| 4 | May 18, 2026 | - | - | |
| 4 | May 18, 2026 | - | - | |
| 8-K | May 14, 2026 | - | Analysis | |
| 8-K | May 7, 2026 | - | Analysis | |
| 10-Q | May 7, 2026 | Mar 31, 2026 | Analysis | |
| 8-K | Apr 14, 2026 | - | Analysis | - |
| 4 | Apr 9, 2026 | - | - | - |
| 4 | Apr 6, 2026 | - | - | - |
| 4 | Apr 6, 2026 | - | - | - |
| 8-K | Apr 2, 2026 | - | Analysis | - |
Related Health Care companies
- AARD · Aardvark Therapeutics, Inc.Pharmaceutical Preparations
- ABT · Abbott LaboratoriesPharmaceutical Preparations
- ABBV · AbbVie IncPharmaceutical Preparations
- ABEO · ABEONA THERAPEUTICS INC.Pharmaceutical Preparations
- ACAD · ACADIA PHARMACEUTICALS INCPharmaceutical Preparations
- ACRS · Aclaris Therapeutics, Inc.Pharmaceutical Preparations
- ACTU · ACTUATE THERAPEUTICS, INC.Pharmaceutical Preparations
- ADCT · ADC Therapeutics SAPharmaceutical Preparations
HRMY SEC filings: frequently asked questions
Are HRMY insiders buying or selling?
In the last 90 days, Harmony Biosciences Holdings, Inc. (HRMY) officers, directors and 10% owners reported no open-market purchases and 7 open-market sales worth $3.1 million by 1 insider on Form 4. Many insider sales are pre-planned or for taxes, so purchases usually carry more information.
Which institutions hold HRMY stock?
As of September 30, 2026, the largest Harmony Biosciences Holdings, Inc. (HRMY) holders among the 13F filers tracked by SignalX were BlackRock ($311.3 million), Vanguard Portfolio Management LLC ($116.6 million), Dimensional Fund Advisors ($104.0 million), Vanguard Capital Management LLC ($86.7 million), State Street Corp ($83.6 million). 13F-HR reports are filed up to 45 days after each quarter ends.
What was HRMY's revenue in fiscal year 2025?
For the fiscal year ended December 31, 2025 (FY2025), Harmony Biosciences Holdings, Inc. (HRMY) reported revenue of $868.5 million (up 21.5% from FY2024) and net income of $158.7 million. Diluted EPS was $2.71. The figures come from the XBRL data in the 10-K.
What are the main risks in HRMY's latest 10-K?
In the 10-K filed February 24, 2026, Harmony Biosciences Holdings, Inc. (HRMY) flagged: Regulatory risk: FDA post-marketing requirements and commitments for WAKIX, including recent approvals for pediatric narcolepsy in June 2024 and February 2026. Geopolitical/macroeconomic risk: reliance on third-party manufacturing with sole-source suppliers and manufacturers, exposing supply chain to disruption risks. (AI summary of the Risk Factors section.)
What did HRMY report in its latest 8-K?
Harmony Biosciences Holdings, Inc. (HRMY) filed an 8-K on November 4, 2026 reporting Item 2.02 (Results of Operations and Financial Condition) and Item 7.01 (Regulation FD Disclosure). Q3 2026 financial results announced for quarter ended September 30, 2026.
What are the latest HRMY SEC filings?
Harmony Biosciences Holdings, Inc. (HRMY) filed its latest 10-K annual report on February 24, 2026, a 10-Q quarterly report on November 4, 2026, an 8-K current report on November 4, 2026 and a Form 4 insider filing on September 18, 2026.
What is HRMY's SEC CIK number?
Harmony Biosciences Holdings, Inc. (HRMY)'s SEC Central Index Key (CIK) is 1802665. EDGAR lists every HRMY filing under that number.
Ask anything about HRMY
The research agent reads HRMY's filings, financials, insider trades and 13F holders, then answers with sources.